Abstract
Tic, short for 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, is a kind of unnatural α-amino acids. Due to its distinct geometrical conformation and biological activity, the structure of Tic, regarded as the surrogate of proline and the rigid analogue of phenylalanine or tyrosine, has been introduced into many compounds, which target diverse enzymes or receptors. The most successful example is that substituting the Tic residue for the proline residue of enalapril led to an approved drug quinapril. In this review, we will summarize the applications and modifications of Tic in peptides and peptidomimetics design and discovery, and hope to spark medicinal researchers inspiration in the field of protein and peptide drug design and optimization.
Keywords: 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic), opioid ligands, farnesyl transferase inhibitors, integrin antagonists, angiotensin-converting enzyme inhibitors, prolyl endopeptidases inhibitors, endogenous mammalian, opiod receptor antagonists, linker, anxiety, depression, schizophrenia, addiction, eating disorders, glycoprotein receptors, immunosupressant
Current Protein & Peptide Science
Title: Applications and Modifications of 1,2,3,4-Tetrahydroisoquinoline-3-Carboxylic Acid (Tic) in Peptides and Peptidomimetics Design and Discovery
Volume: 11 Issue: 8
Author(s): Yingjie Zhang, Hao Fang and Wenfang Xu
Affiliation:
Keywords: 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic), opioid ligands, farnesyl transferase inhibitors, integrin antagonists, angiotensin-converting enzyme inhibitors, prolyl endopeptidases inhibitors, endogenous mammalian, opiod receptor antagonists, linker, anxiety, depression, schizophrenia, addiction, eating disorders, glycoprotein receptors, immunosupressant
Abstract: Tic, short for 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, is a kind of unnatural α-amino acids. Due to its distinct geometrical conformation and biological activity, the structure of Tic, regarded as the surrogate of proline and the rigid analogue of phenylalanine or tyrosine, has been introduced into many compounds, which target diverse enzymes or receptors. The most successful example is that substituting the Tic residue for the proline residue of enalapril led to an approved drug quinapril. In this review, we will summarize the applications and modifications of Tic in peptides and peptidomimetics design and discovery, and hope to spark medicinal researchers inspiration in the field of protein and peptide drug design and optimization.
Export Options
About this article
Cite this article as:
Zhang Yingjie, Fang Hao and Xu Wenfang, Applications and Modifications of 1,2,3,4-Tetrahydroisoquinoline-3-Carboxylic Acid (Tic) in Peptides and Peptidomimetics Design and Discovery, Current Protein & Peptide Science 2010; 11 (8) . https://dx.doi.org/10.2174/138920310794557691
DOI https://dx.doi.org/10.2174/138920310794557691 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of Proteinase-Activated Receptor 1 Antagonists as Therapeutic Agents for Thrombosis, Restenosis and Inflammatory Diseases
Current Pharmaceutical Design The Perfect Storm: A Rheumatologist's Point of View on COVID-19 Infection
Current Rheumatology Reviews Aldosterone to Renin Ratio (ARR) in Clinical use, with Reference to the Primary Care Setting: ARR to Whom, When, How, What for?
Current Hypertension Reviews Psoriatic Arthritis – Review of the Immunologic, Clinic and Therapeutic Aspects of an Inflammatory Systemic Disease
Current Rheumatology Reviews Receptor Binding Ligands to Image Infection
Current Pharmaceutical Design Pulmonary Vasodilators in the Management of Low Cardiac Output Syndrome After Pediatric Cardiac Surgery
Current Vascular Pharmacology Efficacy and Cardiovascular Safety of SGLT2 Inhibitors
Current Drug Safety Simultaneous Determination of Cytochrome P450 Oxidation Capacity in Humans: A Review on the Phenotyping Cocktail Approach
Current Pharmaceutical Biotechnology Subject Index To Volume 4
Current Vascular Pharmacology Immunotherapy of Kidney Cancer
Current Clinical Pharmacology Concerns and Considerations about the Quality Control of Natural Products Using Chromatographic Methods
Current Chromatography Psychotropic Medications and the Treatment of Human Prion Diseases
CNS & Neurological Disorders - Drug Targets Emerging Evidence for Neurotensin Receptor 1 Antagonists as Novel Pharmaceutics in Neurodegenerative Disorders
Mini-Reviews in Medicinal Chemistry Molecular Effects of L-dopa Therapy in Parkinson’s Disease
Current Genomics Indications for Non-Invasive Ventilation in Respiratory Failure
Reviews on Recent Clinical Trials Depression and Vascular Disease: Conceptual Issues, Relationships and Clinical Implications
Vascular Disease Prevention (Discontinued) Paliperidone Use in the Elderly
Current Drug Safety Usefulness of Magnetic Resonance Imaging in Cardiac and Enovascular Intervention
Current Medical Imaging Artificial Blood: A Futuristic Dimension of Modern Day Transfusion Sciences
Cardiovascular & Hematological Agents in Medicinal Chemistry Molecular Properties Prediction and Synthesis of Novel Pyrazoline Carboxamide Analogs as Antitubercular Agents
Anti-Infective Agents